Literature DB >> 12228140

Alosetron: a case study in regulatory capture, or a victory for patients' rights?

Ray Moynihan1.   

Abstract

Entities:  

Keywords:  Health Care and Public Health; Legal Approach

Mesh：

Substances：

Year:  2002        PMID： 12228140      PMCID： PMC1124108          DOI： 10.1136/bmj.325.7364.592

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  7 in total

1.  A pill turned bitter. How a quest for a blockbuster drug went fatally wrong.

Authors:  J P Shapiro
Journal:  US News World Rep       Date:  2000-12-11

2.  Alosetron for irritable bowel syndrome.

Authors:  E Barbehenn; P Lurie; S M Wolfe
Journal:  Lancet       Date:  2000-12-09       Impact factor: 79.321

3.  The FDA and The Lancet: an exchange.

Authors:  A Walker
Journal:  Lancet       Date:  2001-08-04       Impact factor: 79.321

4.  Selling sickness: the pharmaceutical industry and disease mongering.

Authors:  Ray Moynihan; Iona Heath; David Henry
Journal:  BMJ       Date:  2002-04-13

5.  Lotronex and the FDA: a fatal erosion of integrity.

Authors:  R Horton
Journal:  Lancet       Date:  2001-05-19       Impact factor: 79.321

6.  FDA advisers warn of more deaths if drug is relaunched.

Authors:  Ray Moynihan
Journal:  BMJ       Date:  2002-09-14

7.  Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.

Authors:  M Camilleri; A R Northcutt; S Kong; G E Dukes; D McSorley; A W Mangel
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321
  7 in total
  17 in total

1.  Failures of the therapeutic chain as a cause of drug ineffectiveness.

Authors:  Albert Figueras; Joan-Ramon Laporte
Journal:  BMJ       Date:  2003-04-26

2.  We need Romanow's National Drug Agency.

Authors: 
Journal:  CMAJ       Date:  2003-02-04       Impact factor: 8.262

Review 3.  Pharmacology of serotonin: what a clinician should know.

Authors:  F De Ponti
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

4.  Bias in research and conflict of interest: why should we care?

Authors:  H P Dietz
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-11-21

5.  Preemption, tort reform, and pharmaceutical claims: Part two: Has the Food and Drug Administration shown it is solely responsible for the protection of patients? Can it do so? Will it do so?

Authors:  Russell G Thornton
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-01

Review 6.  Drugs and Medical Devices: Adverse Events and the Impact on Women's Health.

Authors:  Jennifer L Carey; Nathalie Nader; Peter R Chai; Stephanie Carreiro; Matthew K Griswold; Katherine L Boyle
Journal:  Clin Ther       Date:  2017-01-07       Impact factor: 3.393

Review 7.  Reporting bias in medical research - a narrative review.

Authors:  Natalie McGauran; Beate Wieseler; Julia Kreis; Yvonne-Beatrice Schüler; Heike Kölsch; Thomas Kaiser
Journal:  Trials       Date:  2010-04-13       Impact factor: 2.279

8.  Professional Conferences, Unprofessional Conduct.

Authors:  A C Anand
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 9.  Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder.

Authors:  Anthony Lembo; H Christian Weber; Francis A Farraye
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 10.  Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome?

Authors:  Viola Andresen; Stephan Hollerbach
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.